Health on MSN

Cranberries vs. blueberries: Which is better for antioxidants and fiber?

Medically reviewed by Kayla Girgen, RD Antioxidant-rich cranberries and blueberries support heart, immune, and digestive health.They have similar amounts of fiber, but blueberries have more vitamin K ...
Horse & Hound

How to feed a horse on box rest to maintain health and aid recovery

Expert advice from equine vet Edward Busuttil MRCVS on how to feed a horse on box rest to help maintain their mental and ...

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Affluent Medical announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies. -2-

DJ Affluent Medical announces upcoming acquisition of Caranx Medical and Artedrone, becoming Carvolix, pioneering cardiovascular therapies. Affluent Medical Affluent Medical announces upcoming acquisi ...

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers ...

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-en ...
Healthy Debate

‘How would the average Canadian know to ask?’ Men left in the dark on minimally invasive prostate cancer treatments

For many men, prostate cancer is not just a question of survival. It is a question of how they will live afterward.
Longevity LIVE

Building A Solid Health Plan For Your Healthspan

Longevity is less about how long you live and more about health span. The length of time you’re healthy – living happier and healthier.
Le Lézard

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...